Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

ClinicalTrials.gov ID: NCT03564340

Public ClinicalTrials.gov record NCT03564340. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 17, 2026, 9:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2 Study of REGN4018 (Ubamatamab), a MUC16×CD3 Bispecific Antibody, Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer or Other Recurrent MUC16+ Cancers

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The main purpose of this study is to: * Learn about the safety of ubamatamab and to find out what dose of ubamatamab can be given alone or with cemiplimab to patients with ovarian cancer or cancer of the uterus * The study will also look at the levels of ubamatamab and/or cemiplimab in the body and measure how well the body can remove the study drug(s). This is called pharmacokinetics * The study will also look at any signs that ubamatamab alone or with cemiplimab can treat recurrent advanced ovarian cancer or cancer of the uterus * To find out how safe and tolerable pretreatment is in combination with ubamatamab and to see how well it works to prevent or minimize Cytokine Release Syndrome (CRS)

Study identification

NCT ID: NCT03564340
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Regeneron Pharmaceuticals; Industry
Enrollment: 890 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: Female
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 21, 2018 (Actual)
Primary completion: May 10, 2027 (Estimated)
Completion: May 10, 2027 (Estimated)
Last update posted: Sep 25, 2026

2018 – 2027

United States locations

U.S. sites: 12
U.S. states: 9
U.S. cities: 10

Facility	City	State	ZIP	Site status
University of Alabama_6th Ave	Birmingham	Alabama	35294	Recruiting
Massachusetts General Hospital	Boston	Massachusetts	02114	Recruiting
Dana Farber / Harvard Cancer Center	Boston	Massachusetts	02215	Recruiting
Mayo Clinic - Rochester	Rochester	Minnesota	55901	Recruiting
Roswell Park Cancer Institute	Buffalo	New York	14263	Withdrawn
Columbia University Medical Center	New York	New York	10032	Recruiting
Memorial Sloan Kettering Cancer Center	New York	New York	10065	Recruiting
The Ohio State University Wexner Medical Center	Columbus	Ohio	43210	Recruiting
Stephenson Cancer Center	Oklahoma City	Oklahoma	73104	Recruiting
Sarah Cannon Research Institute	Nashville	Tennessee	37203	Completed
The University of Texas MD Anderson Cancer Center	Houston	Texas	77030	Recruiting
Virginia Commonwealth University	Richmond	Virginia	23219	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 42 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03564340, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 25, 2026 · Synced Oct 17, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT03564340 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →